Active Contrast Encoding MRI for Breast Cancer

乳腺癌主动对比编码 MRI

• 批准号: 9765502
• 负责人: Sungheon Gene Kim
• 金额: $ 55.02万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9765502
• 关键词: 3-Dimensional; Address; Angiogenesis Inhibitors; Animals; Area; Blood Cells; Blood Vessels; Blood flow; Blood specimen; Breast Cancer Model; Breast Magnetic Resonance Imaging; Cancer Etiology; Cancer Model; Cell Death; Cell Size; Cells; Cellular Membrane; Cessation of life; Clinical; Combined Modality Therapy; Contrast Media; Cytotoxic agent; Data; Development; Diffusion Magnetic Resonance Imaging; Distant; Distant Metastasis; Drug Delivery Systems; Excision; Extracellular Space; Failure; Funding; Gadolinium; Harvest; Human; Image; Imaging technology; Immune; Immunotherapy; Ion Channel; Life; Magnetic Resonance Imaging; Malignant Neoplasms; Measurement; Measures; Methods; Monitor; Mus; Neoadjuvant Therapy; Neoplasm Metastasis; Operative Surgical Procedures; Pathologic; Pathology; Patients; Perfusion; Physiologic pulse; Plasma; Positron-Emission Tomography; Property; Protocols documentation; Protons; Radial; Research; Scanning; Surface; Techniques; Testing; Three-Dimensional Imaging; Time; Tissues; Translating; Triplet Multiple Birth; Uncertainty; Validation; Vascular Permeabilities; Water; Woman; base; bioluminescence imaging; cancer cell; cancer diagnosis; cancer imaging; cancer therapy; chemotherapy; clinical application; cohort; contrast enhanced; cytotoxic; data acquisition; drug discovery; experimental study; grasp; image reconstruction; imaging modality; improved; in vivo; in vivo imaging; innovation; interstitial; malignant breast neoplasm; metabolic rate; novel; novel strategies; response; temporal measurement; treatment response; tumor; water channel

PROJECT SUMMARY Despite recent development of various new approaches to therapy, breast cancer remains the second leading cause of cancer death in women. Treatment with anti-angiogenic drugs combined with conventional cytotoxic drugs or immunotherapy is a promising means of treating aggressive cancer. Anti-angiogenic drugs are thought to temporarily normalize abnormal vasculature and paradoxically increase blood flow and hence delivery of drug and effector immune cells to tumors. However, a substantial proportion of patients do not respond to this combination therapy and it is unclear whether the failure is due to failure of the anti-angiogenic to normalize the vasculature or failure of the cytotoxic drugs or immune cells to kill cancer cells. It is therefore necessary to assess both blood flow and cell death to elucidate the mechanism and to optimize the combination treatments. In this proposal we investigate a single MRI acquisition and analysis that will allow assessment of both. Dynamic contrast enhanced (DCE) MRI has been widely used as an important part of most clinical MRI exams for diagnosis of cancer, and it holds high potential as a single MRI method to estimate both perfusion parameters (such as, flow, F, vascular volume fraction, vp, and vascular permeability-surface area product, PS) and cellular parameters (such as, interstitial volume fraction, ve, and intracellular water life time, τi). Recently, we developed a novel data acquisition method, namely active contrast encoding (ACE)-MRI, which measures dynamic data together with pre-contrast T1 and B1 that are critical for measurement of perfusion and cellular parameters. ACE-MRI is also implemented with a fast 3D imaging method to acquire high-spatial and high- temporal resolution data using a 3D golden-angle ultra-short echo-time (UTE) sequence and an image reconstruction method to combine both compressed sensing and parallel imaging, also known as GRASP (Golden-angle RAdial Sparsity and Parallel). In this study, we plan to further develop ACE-MRI for accurate estimation of contrast agent concentration in vascular plasma and tissue using a direct blood sampling method (Aim 1), and to assess the association of τi with tumor metabolic rate and treatment response in comparison with 18F-FDG-PET and pathology (Aim 2). Overall, the ACE-MRI parameters will be used to assess treatment response and metastatic potential (Aim 3). This study will be conducted with murine and human breast cancer models at a 7T small animal MRI scanner. However, the methods developed in this study can be easily translated to clinical applications as it is used on a UTE sequence readily available on most clinical scanners.

项目摘要 尽管最近开发了各种新治疗方法，但乳腺癌仍然是第二大领先 女性癌症死亡的原因。用抗血管生成药物结合常规细胞毒性药物治疗 药物或免疫疗法是治疗攻击性癌症的承诺含义。抗血管生成药物是 被认为是暂时使异常脉管系统正常正常的，并且矛盾地增加了血流，因此 将药物和效应的免疫细胞递送到肿瘤中。但是，很大一部分患者没有 应对这种组合疗法，目前尚不清楚失败是由于抗血管生成的失败而导致的 使细胞毒性药物或免疫细胞杀死癌细胞的脉管系统或失败。因此是 评估血流和细胞死亡的必要条件，以阐明机制并优化 组合治疗。在此提案中，我们调查了一次MRI获取和分析，这将允许 两者的评估。 动态对比增强（DCE）MRI已被广泛用作大多数临床MRI的重要组成部分 检查癌症的诊断检查，并且具有很高的潜力作为单一MRI方法，可以估算两种灌注 参数（例如，流量，F，血管体积分数，VP和血管通透性 - 表面面积产品，PS） 和细胞参数（例如，间质体积分数，VE和细胞内水寿命，τi）。最近， 我们开发了一种新型的数据采集方法，即主动对比编码（ACE）-MRI，它测量了 动态数据以及前对比的T1和B1，对于灌注和细胞的测量至关重要 参数。 ACE-MRI还采用快速的3D成像方法实施，以获取高空间和高位 使用3D黄金角度超短回声（UTE）序列和图像的临时分辨率数据 结合压缩感应和并行成像的重建方法，也称为grasp （金角径向稀疏性和平行）。 在这项研究中，我们计划进一步开发ACE-MRI，以准确估计造影剂的浓度 使用直接抽样方法（AIM 1）的血管血浆和组织，并评估τi的关联 与18F-FDG-PET和病理学相比，肿瘤代谢率和治疗反应（AIM 2）。 总体而言，ACE-MRI参数将用于评估治疗反应和转移潜力（AIM 3）。 这项研究将在7T小动物MRI扫描仪上使用鼠和人类乳腺癌模型进行。 但是，本研究中开发的方法可以轻松地转化为临床应用，因为它用于 大多数临床扫描仪都可以使用UTE序列。